Randomised Double Blind Placebo Controlled Cross Over Design of the Efficacy of Topical Morphine for Inflammatory Pain in Children With Epidermolysis Bullosa
Phase 4
Completed
- Conditions
- Epidermylosis Bullosa
- Registration Number
- NCT00231517
- Lead Sponsor
- Institute of Child Health
- Brief Summary
Randomised Double blind placebo controlled cross over design study of the efficacy of morphine for inflammatory pain in children with Epidermolysis Bullosa
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- children under 18 years epidermolysis wounds requiring dressing changes
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie inflammatory pain in children with recessive dystrophic epidermolysis bullosa?
How does topical morphine compare to standard-of-care analgesics for managing inflammatory pain in epidermolysis bullosa patients?
Are there specific biomarkers that predict analgesic response to topical opioids in epidermolysis bullosa subtypes?
What are the potential adverse events associated with long-term topical morphine use in pediatric epidermolysis bullosa populations?
What combination therapies show promise for inflammatory pain management in epidermolysis bullosa beyond morphine-based approaches?
Trial Locations
- Locations (1)
Great Ormond Street Hospital and the Institute of Child health
🇬🇧London, United Kingdom
Great Ormond Street Hospital and the Institute of Child health🇬🇧London, United Kingdom